Retatrutide 12mg

What is Retatrutide?

Retatrutide is a novel, triple-hormone receptor agonist being developed by Eli Lilly and Company. It represents the next potential major advancement in the treatment of obesity and type 2 diabetes, following the success of dual-agonists like Tirzepatide.

Its key differentiator is its “triple-agonist” mechanism.

Mechanism of Action: The “Triple G” Agonist

Retatrutide works by simultaneously activating three key hormone receptors in the body:

1. GIP Receptor (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin secretion and improves energy metabolism.

2. GLP-1 Receptor (Glucagon-like Peptide-1): Suppresses appetite, slows gastric emptying, and stimulates insulin secretion.

3. Glucagon Receptor: This is the new component. Activating the glucagon receptor increases energy expenditure (calories burned) by the liver and body. It also helps with fat metabolism.

This triple action creates a powerful synergistic effect on blood sugar control and, especially, weight loss.

---

The 12 mg Dose in Context

The 12 mg dose is a key milestone in the studied dosing schedule for Retatrutide.

• Dosing Schedule in Trials: In the Phase 2 trial, the treatment schedule was designed to slowly ramp up the dose to minimize side effects. The schedule went as follows:

  • Start at 2 mg, then increase to 4 mg, 8 mg, and then to 12 mg.

• Maintenance vs. Escalation: After reaching 12 mg, the dose was continued for the remainder of the study for some participants. For others, it was further escalated to a higher dose. This means 12 mg can be both a maintenance dose and a step towards an even higher dose, depending on the treatment plan.

Efficacy of the 12 mg Dose

The results from the Phase 2 trial were striking, and the 12 mg dose was a major contributor to these findings.

For Weight Loss (at 48 weeks):

• Participants on the 12 mg dose achieved very significant weight loss.

• In the trial, the group that was titrated up to 12 mg and maintained on it lost, on average, approximately 17% of their body weight at the 48-week mark.

• For comparison, this is significantly more weight loss than what was seen with the highest doses of semaglutide (Wegovy) at a similar timepoint.

For Type 2 Diabetes (A1c Reduction):

• The trial also showed powerful glucose-lowering effects. Patients with type 2 diabetes saw dramatic reductions in HbA1c.

It’s important to note that the highest doses in the study (above 12 mg) showed even greater efficacy, with some patients achieving over 24% weight loss at 48 weeks, but with a corresponding increase in side effects.